N-(4-(2-Propylhydrazinecarbonyl)phenyl)benzamide

ID: ALA4465293

PubChem CID: 155531159

Max Phase: Preclinical

Molecular Formula: C17H19N3O2

Molecular Weight: 297.36

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CCCNNC(=O)c1ccc(NC(=O)c2ccccc2)cc1

Standard InChI:  InChI=1S/C17H19N3O2/c1-2-12-18-20-17(22)14-8-10-15(11-9-14)19-16(21)13-6-4-3-5-7-13/h3-11,18H,2,12H2,1H3,(H,19,21)(H,20,22)

Standard InChI Key:  JYBYRHHEZONZJB-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 22 23  0  0  0  0  0  0  0  0999 V2000
    2.6895  -11.1848    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6884  -12.0043    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3964  -12.4133    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1061  -12.0038    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1033  -11.1812    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3946  -10.7759    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8144  -12.4113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5215  -12.0016    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.2299  -12.4091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2265  -13.2247    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9340  -13.6321    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6421  -13.2224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6382  -12.4009    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9301  -11.9972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3510  -13.6289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3533  -14.4461    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.0575  -13.2183    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.7664  -13.6248    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.4729  -13.2142    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1818  -13.6207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8883  -13.2101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8157  -13.2285    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  4  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14  9  1  0
 12 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
  7 22  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA4465293

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 297.36

Molecular Weight (Monoisotopic): 297.1477

AlogP: 2.58

#Rotatable Bonds: 6

Polar Surface Area: 70.23

Molecular Species: NEUTRAL

HBA: 3

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 3.86

CX LogP: 2.72

CX LogD: 2.72

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.57

Np Likeness Score: -1.29

References

1. Li X, Jiang Y, Peterson YK, Xu T, Himes RA, Luo X, Yin G, Inks ES, Dolloff N, Halene S, Chan SSL, Chou CJ..  (2020)  Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.,  63  (10): [PMID:32321249] [10.1021/acs.jmedchem.0c00442]

2. Pulya S, Patel T, Paul M, Adhikari N, Banerjee S, Routholla G, Biswas S, Jha T, Ghosh B..  (2022)  Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer.,  238  [PMID:35635949] [10.1016/j.ejmech.2022.114470]

Source

Source(1):

• Scientific Literature